Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxaneยฎ is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
Surgery With or Without Preoperative Chemotherapy in Treating Patients With Resectable Non-small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 600
- Registration Number
- NCT00003159
- Locations
- ๐ฌ๐ง
Medical Research Council Clinical Trials Unit, London, England, United Kingdom
๐ฌ๐งRoyal Marsden NHS Foundation Trust - Surrey, Sutton, England, United Kingdom
Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-05-19
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 659
- Registration Number
- NCT00006011
- Locations
- ๐บ๐ธ
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 21
- Registration Number
- NCT00030654
- Locations
- ๐บ๐ธ
Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States
๐บ๐ธPenrose Cancer Center at Penrose Hospital, Colorado Springs, Colorado, United States
๐บ๐ธHope Cancer Care Center at Longmont United Hospital, Longmont, Colorado, United States
S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 77
- Registration Number
- NCT00045630
- Locations
- ๐บ๐ธ
Providence Saint Joseph Medical Center - Burbank, Burbank, California, United States
๐บ๐ธUSC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
๐บ๐ธHurley Medical Center, Flint, Michigan, United States
Radiation Therapy Plus Paclitaxel and Cisplatin in Treating Patients With Cervical Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 40
- Registration Number
- NCT00003379
- Locations
- ๐บ๐ธ
University of Mississippi Medical Center, Jackson, Mississippi, United States
๐บ๐ธMBCCOP - University of Illinois at Chicago, Chicago, Illinois, United States
๐บ๐ธIreland Cancer Center, Cleveland, Ohio, United States
Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 48
- Registration Number
- NCT00003385
- Locations
- ๐บ๐ธ
MBCCOP - Hawaii, Honolulu, Hawaii, United States
๐บ๐ธIreland Cancer Center, Cleveland, Ohio, United States
๐บ๐ธHolden Comprehensive Cancer Center, Iowa City, Iowa, United States
Oxaliplatin and Paclitaxel in Treating Patients With Metastatic or Unresectable Cancer
- Conditions
- Locations
- ๐บ๐ธ
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
S0007 - Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-04-10
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 78
- Registration Number
- NCT00006248
- Locations
- ๐บ๐ธ
MBCCOP - Gulf Coast, Mobile, Alabama, United States
๐บ๐ธJonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
๐บ๐ธVeterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 842
- Registration Number
- NCT00021060
- Locations
- ๐บ๐ธ
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
Bevacizumab, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 8
- Registration Number
- NCT00025389
- Locations
- ๐บ๐ธ
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University, Columbus, Ohio, United States
๐บ๐ธUniversity of Chicago Cancer Research Center, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.